• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Trinity Biotech plc

    3/31/25 12:15:06 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TRIB alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: March 28, 2025 4:00 P.M.
    Form: F-3
    CIK: 0000888721
    Company Name: TRINITY BIOTECH PLC
    File Number: 333-286020
    Get the next $TRIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRIB
    Leadership Updates

    Live Leadership Updates

    See more
    • Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

      DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and

      3/13/25 7:30:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

      DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) --  Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We are resolute in continuing to execute on our transformation agenda, which will drive greater performance and profitability in our existing product lines, including supporting continued growth in our newest r

      9/3/24 9:55:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

      DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We remain focused on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver for Trinity Biotech, and we

      8/20/24 5:00:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $TRIB
    SEC Filings

    See more
    • SEC Form 6-K filed by Trinity Biotech plc

      6-K - TRINITY BIOTECH PLC (0000888721) (Filer)

      5/15/25 4:17:20 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form NT 20-F filed by Trinity Biotech plc

      NT 20-F - TRINITY BIOTECH PLC (0000888721) (Filer)

      4/30/25 4:36:31 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by Trinity Biotech plc

      6-K - TRINITY BIOTECH PLC (0000888721) (Filer)

      4/4/25 8:39:18 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $TRIB
    Financials

    Live finance-specific insights

    See more

    $TRIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TRIB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its Comprehensive Transformation Plan, many of which are now completed or at the final stages of execution and expected to deliver near term profitability improvements: Consolidation & Offshore Manufacturing: We ob

      5/15/25 4:00:39 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

      DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares ("ADSs") for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed

      3/14/25 4:30:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

      DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors. The additional liquidity will support both the continued development of Trinity Biotech's innovative continuous glucose monitoring (CGM) technology and the Company's comprehensive transformation plan. The Company continues to focus much of its growth efforts around its CGM technology, especially given the previously announced positive results from its mos

      2/28/25 8:30:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

      SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

      11/14/24 5:26:28 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

      SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

      5/1/24 4:57:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Trinity Biotech plc

      SC 13D - TRINITY BIOTECH PLC (0000888721) (Subject)

      2/9/24 7:51:28 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its Comprehensive Transformation Plan, many of which are now completed or at the final stages of execution and expected to deliver near term profitability improvements: Consolidation & Offshore Manufacturing: We ob

      5/15/25 4:00:39 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

      DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares ("ADSs") for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed

      3/14/25 4:30:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

      DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and

      3/13/25 7:30:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care